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Abstract
Background: Within estrogen receptor-positive breast cancer (ER+ BC), the expression levels of
proliferation-related genes can define two clinically distinct molecular subtypes. When treated with
adjuvant tamoxifen, those ER+ BCs that are lowly proliferative have a good prognosis (luminal-A
subtype), however the clinical outcome of those that are highly proliferative is poor (luminal-B
subtype).
Methods: To investigate the biological basis for these observations, gene set enrichment analysis
(GSEA) was performed using microarray data from 246 ER+ BC samples from women treated with
adjuvant tamoxifen monotherapy. To create an in vitro model of growth factor (GF) signaling
activation, MCF-7 cells were treated with heregulin (HRG), an HER3 ligand.
Results: We found that a gene set linked to GF signaling was significantly enriched in the luminal-
B tumors, despite only 10% of samples over-expressing HER2 by immunohistochemistry. To
determine the biological significance of this observation, MCF-7 cells were treated with HRG.
These cells displayed phosphorylation of HER2/3 and downstream ERK and S6. Treatment with
HRG overcame tamoxifen-induced cell cycle arrest with higher S-phase fraction and increased
anchorage independent colony formation. Gene expression profiles of MCF-7 cells treated with
HRG confirmed enrichment of the GF signaling gene set and a similar proliferative signature
observed in human ER+ BCs resistant to tamoxifen.
Conclusion: These data demonstrate that activation of GF signaling pathways, independent of
HER2 over-expression, could be contributing to the poor prognosis of the luminal-B ER+ BC
subtype.
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Background
Gene expression profiling has given new insight into the
heterogeneity of estrogen receptor positive breast cancers
(ER+ BC). In particular, much interest has focused on pre-
dicting resistance in tamoxifen-treated patients, given the
emergence of alternative anti-estrogen therapies and tar-
geted biological agents [1]. There are several predictive
gene sets and assays that have been developed to identify
groups of ER+ BC that have a poor clinical outcome
despite tamoxifen treatment [2-6]. Previously, by using a
meta-analytical approach in over 2800 breast cancers, we
have shown that proliferation and cell cycle-related genes
are the most powerful predictors of prognosis in breast
cancer and seems to be the common biological signal
linking many of these prognostic predictors, despite the
different methods of discovery and lack of significant gene
overlap [6-8]. Using a quantitative proliferation index
called a Grade Gene-expression Index (GGI- genomic
grade) [8], we were able to divide ER+ BC according to
their cellular proliferative activity into two prognostic
groups associated with statistically distinct clinical out-
come [6]. These subgroups are highly correlated to other
commonly cited molecular classifications of breast cancer:
the luminal A/B classification [9] and the good and poor
prognostic subgroups produced by the 21-gene Recur-
rence Score [4,6] similar to the low and high genomic
grade ER+ BC subtypes respectively.
However, whilst many gene classifiers exist for predicting
prognosis in women with ER+ BC treated with tamoxifen,
there has been little focused biological investigation into
the mechanisms that could be contributing to the relative
tamoxifen resistance and the increased proliferative activ-
ity in the high risk, luminal-B ER+ BC subtype. Elucida-
tion of the relevant dysfunctional pathways would
ultimately lead to new strategies to treat the poor progno-
sis subgroup and may eventually prove a more clinically
relevant way to stratify treatment options for breast cancer
patients. Whilst gene expression data has demonstrated its
ability to identify subsets of disease, predict disease out-
come or response to therapeutics [9-13], extracting useful
biological data from whole genome microarray data to
identify new therapeutic approaches in the clinical setting
remains a significant challenge. Recently, a new computa-
tional method of analysis known as gene-set enrichment
analysis (GSEA) [14] has provided a new approach of
identifying potentially relevant oncogenic pathways that
may be correlated with particular phenotypes. This path-
way orientated approach has advantages over the individ-
ual gene analyses which can often fail to put genes into
context and can be difficult to reproduce across different
datasets. This concept was originally demonstrated in a
study which identified a set of genes involved in oxidative
phosphorylation, whose expression was concurrently
decreased in human diabetic muscle when no single gene
was significant by classical analysis, emphasizing the
importance of elucidating pathway relationships [15].
However GSEA still remains hypothesis generating and
requires experimental validation. Bearing this in mind, we
report the use of GSEA to generate hypotheses about dys-
functional biological pathways that could be driving pro-
liferation and contributing to the poor outcome of the
tamoxifen-treated, highly proliferative (luminal-B) ER+
BC subtype.
Methods
Human breast cancer microarray dataset
Our current analysis uses a microarray dataset of 246
early- stage breast cancer samples, all of whom were clas-
sified as estrogen receptor (ER) positive and had received
adjuvant tamoxifen monotherapy only. These samples
have been previously used in another study (methods and
demographics are described in Loi et al. [6] with the raw
data available at the Gene Expression Omnibus (GEO)
repository database http://www.ncbi.nlm.nih.gov/geo/,
accession code GSE6532. Microarray analysis was per-
formed with Affymetrix™ U133A Genechips® (Affymetrix,
Santa Clara, CA) according to Affymetrix™ protocols.
There were 99 tumors classified as highly proliferative
(high-risk, luminal-B ER+ BC subtype) tumors and 147
lowly proliferative (low-risk, luminal-A ER+ BC subtype)
tumors used for this analysis. Each hospital's institutional
ethics board approved the use of the tissue material for
research purposes.
Data was also analyzed through the use of Ingenuity Path-
ways Analysis (http://www.ingenuity.com; Ingenuity Sys-
tems, Redwood City, CA) version 6.0.
Gene set enrichment analysis (GSEA)
Gene set enrichment analysis was performed using the
GSEA software version 1.0 developed by Subramanian
and colleagues at the Broad Institute [14]http://
www.broad.mit.edu/gsea/. For this analysis we compared
low and high-risk ER+ subtypes and looked for enrich-
ment of the C2 curated catalogue of functional genes sets.
We also curated from the literature gene sets representing
ERBB2/growth factor activation from Perou et al (see
Additional file 1) [9], androgen receptor [16], RAS, MYC
SRC, E2F3 and β-Catenin [17] oncogenic pathway dysreg-
ulation. 1000 permutations were used to test significance
of enrichment.
In brief, GSEA is a supervised method of elucidating dif-
ferential expression (enrichment) of gene sets from gene
expression data. These sets contain genes that share or
relate to a common biological function and are deter-
mined a priori. The computational method ranks all genes
in the data set based on their correlation with the two phe-
notypes being compared (in this case low vs. high-riskBMC Medical Genomics 2009, 2:37 http://www.biomedcentral.com/1755-8794/2/37
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ER+ BC subtypes). It then identifies the rank positions of
the members of the specified gene set in relation to either
phenotype and calculates an enrichment score (ES) which
reflects the degree to which a gene set is over represented
at the extremes. The class labels are then permutated to
compare the ES obtained by the specific gene set to that
obtained across random classes to calculate a p value for
enrichment. To control for multiple hypothesis testing, a
false discovery rate (FDR) is calculated to control the pro-
portion of false positives.
Cell Culture and treatment
MCF-7 and SK-BR3 cells were grown at 37°C, 5% CO2 in
phenol-red free Improved Modified Eagle's medium
(IMEM) supplemented with 5% fetal bovine serum. Cells
were plated in 100 mm dishes and grown to 80% conflu-
ence. To create an in vitro model the highly proliferative
ER+ subtype with growth factor (GF) pathway activation,
MCF-7 cells were treated with heregulin-beta 1 [HRG-
CytoLab/Peprotech Asia] [18]. Before treatment, cells
were serum starved for 24 hours. Cells were then treated
with vehicle (ethanol), estrogen [E2- Sigma] (1 nM),
tamoxifen [TAM] (4-hydroxy-tamoxifen-Sigma, 100 nM),
heregulin-beta 1 [HRG- CytoLab/Peprotech Asia] (10 ng/
mL) or tamoxifen and heregulin [TAM-HRG] (same con-
centrations) for 24 hours (the cells treated for western blot
analysis were incubated for 20 minutes in the presence of
the relevant stimulus) prior to collection.
Cell cycle analysis
Cells described above were collected for cell cycle analysis.
Cells were analyzed using flow cytometric analysis. Cells
were labeled with Bromodeoxyuridine (BrdU, Sigma) and
then fixed and stained with bromodeoxyuridine-conju-
gated FITC and propidium iodide. BrdU was detected with
anti-BrdU (Becton Dickinson) and cell cycle analysis was
carried out using a Becton Dickinson FACScan.
Antibodies
Antibodies against ERB2 (# 2242), ERB3 (# 4754), phos-
phorylated ERB2 (Tyr877; # 2241), ERB3 (Tyr1289; #
4791), tyrosine (P-Tyr-100; # 9411), AKT (S473; # 9271,
S6 (S235/236; # 2211) and ERK (T202/Y204; # 9101)
were obtained from Cell Signaling and β actin from MP
Biomedicals. Cell Signaling antibodies were used at
1:1000 dilution and β actin at 1:20,000.
Immunoblots
After treatment, cells were rinsed in PBS and lysed for 20
min in ice cold 1% NP40 lysis buffer (50 mM Tris-HCl pH
7.5, 120 mM NaCl, 1 mM EDTA, 50 mM NaF, 40 mM β-
glycerophosphate, 0.1 mM Na3VO4, 1 mM benzamidine,
1% NP40,1 mM PMSF, 1 protease inhibitor cocktail tablet
– Roche –/10 ml lysis buffer). Cellular debris was
removed by 2 × 10 min centrifugation at 4°C. Protein
concentration was determined in the supernatants by
Lowry (BioRad kit) and aliquots of 50 (g proteins were
separated in reducing denaturing conditions by standard
SDS-PAGE gel electrophoresis on 10% gels. SK-BR-3 cell
lysates (+/- HRG) were run on each gel as controls for
HER2 overexpression. Blotting of proteins, incubation
with antibodies and protein detection was done as previ-
ously described using the LiCor Odyssey infrared Imaging
System (Biosciences) [19]. Cell lysates were collected
Clonogenic survival assays
MCF-7 cells were plated at 2000 cells per 60 mm plate.
Twenty-four hours later, cells were treated with drugs at
the specified doses and incubated in normal medium con-
taining drug for 12 days, after which they were fixed in
90% methanol, and stained with 0.1% crystal violet. Col-
onies of >50 cells were enumerated.
Anchorage independent growth assays
The ability of HRG treated MCF-7 cells to stimulate
anchorage-independent growth in the presence of TAM
was tested by soft agar assay. Colony forming assays in
soft agarose were performed. In brief, 4000 cells (sus-
pended in IMEM phenol-red free medium supplemented
with 5% fetal bovine serum) in 0.35% bactoagar with dif-
ferent treatments were grown on the bottom layer of
solidified 0.6% bactoagar in 35 mm dishes. After 10 days
the colonies on the top layer were enumerated. The size
exclusion limit for a positive colony counting was ~60 μm
diameter.
Microarray experiments of cell lines
To determine if the ERBB2/growth factor activation gene
set was enriched in an in vitro model of the high-risk ER+
subtype, MCF-7 cells that were serum starved for 24 hours
by culturing the cells in IMEM containing 0.1% serum.
Cells were then stimulated with HRG before RNA was
extracted using TriZOL (Invitrogen) and compared with
untreated serum starved MCF-7 cells. Microarray analysis
was performed according to standard Affymetrix proto-
cols: biotinylated targets were prepared by published
methods (Affymetrix, Santa Clara, CA, USA) and hybrid-
ized to the Affymetrix oligonucleotide microarray U133
Plus GeneChip®. Arrays were scanned using standard
Affymetrix protocols. Gene expression values from the
CEL files were normalized by use of the standard quantile
normalization method in RMA [20]. Gene expression pro-
files were then uploaded into GSEA and analyzed for
enrichment (MCF untreated controls vs. MCF-7 cells
treated with HRG).
Proliferation status of these cell lines was assessed and
compared by calculating their "Grade Gene expression
Index" (GGI) as previously described [8] and by assessing
for significance of cell cycle related gene sets. In this wayBMC Medical Genomics 2009, 2:37 http://www.biomedcentral.com/1755-8794/2/37
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we could determine if the MCF-7 cells treated with HRG
had a higher GGI, i.e. higher expression of proliferation
genes compared with untreated MCF-7 cells. Cell samples
corresponding to each treatment were arrayed in tripli-
cate.
Statistical Analysis
Values are expressed as means with 95% confidence inter-
vals (CIs). The effects of drug treatment (TAM, HRG,
HRG+TAM) on MCF-7 cells were compared by the % S
phase of serum-starved cells using a two sample t test. P ≤
0.05 was set as the criteria for statistical significance.
Experiments were done in triplicate and repeated three
times.
Results
GSEA analysis of high-risk (luminal-B) and low (luminal-A) 
ER+ BC subtypes
Previously we have reported that a ER+ BC subtype defined
by high levels of expression of proliferation genes has a poor
outcome on adjuvant tamoxifen monotherapy by analyzing
249 archival tissue samples from women diagnosed with
early-stage breast cancer [6]. We applied GSEA to identify
gene sets correlated with the poor prognosis ER+ BC subtype.
Using a p value of <0.05 and false discovery rate (FDR) of ≤
0.20, there were 78 significant gene sets (Additional file 2).
Many of these gene sets were, as expected, related to cell cycle
function. Interestingly, there were a number of gene sets
related to metabolic and apoptosis pathways. We were also
interested to note the significance of the ERBB2 gene set (p =
0.02, FDR = 0.09), given that only a minority of these sam-
ples over-expressed HER2 by immunohistochemisty (+3).
After excluding these samples (10%) we found that this gene
set remained significantly enriched in the high risk ER+ BC
subtype (p < 0.001, FDR = 0.01). It is known that overexpres-
sion of HER2 leads to tamoxifen resistance [21] but as the
ERBB2 gene set could also represent signaling in response to
any other growth factor, we hypothesized that it was activa-
tion of the downstream mediators of this pathway that could
be playing an important role in contributing to the poor
prognosis molecular subtype's phenotype of high prolifera-
tion and tamoxifen resistance. To further examine the bio-
logic function of the ERBB2 gene set, we performed
Ingenuity Pathway analysis (IPA). Neuregulin signaling was
ranked the second top significant canonical pathway (p =
0.005) supporting the hypothesis that this gene set repre-
sented growth factor (GF) signaling (Additional file 3).
HRG- treated MCF-7 breast cancer cells as a biological 
model for growth factor signaling pathway activation
To create a model of growth factor (GF) pathway signaling
activation, MCF-7 cells were treated with heregulin (HRG)
[18]. MCF-7 cells normally express low or normal levels of
HER2 and HER3 is found in HER2 immunoprecipitates
when MCF-7 cells are treated with the HER3 ligand, HRG
[18]. As seen in Figure 1a, MCF-7 cells treated with HRG
do not over-express HER2 protein compared with SK-BR3
breast cancer cells that are known to contain amplified
ERRB2. However, HRG stimulates phosphorylation of
HER2 and HER3 at levels above untreated MCF-7 cells
despite the lack of HER2 overexpression (Figure 1b).
Phosphorylation of AKT, ERK/MAPK, and S6 were also
induced by HRG, further supporting activation of GF sig-
naling in response to stimulation by HRG.
HRG-induced growth factor signaling results in resistance 
to tamoxifen in MCF-7 cells
Next, we sought to determine if our model of HRG-
induced GF pathway activation could induce resistance to
tamoxifen. Tamoxifen's effects on the growth of MCF-7
cells were assessed by clonogenic and anchorage inde-
pendent growth assays. As expected, treatment of MCF-7
cells with estrogen increased both clonogenic (p = 0.01)
and anchorage-independent colony formation (p =
0.001) and treatment with tamoxifen reduced it (p =
0002, p = 6.9 × 10-12 respectively) (Figure 2a, b). However,
treatment with HRG overcame tamoxifen's growth inhib-
itory effects on MCF-7 cells in both clonogenic (p = 6.7 ×
10-7) and anchorage-independent (p = 1.4 × 10-6) assays.
Together, these data demonstrate that our in vitro model
of GF pathway activation, as evidenced by phosphoryla-
tion of HER2, HER3, ERK and S6 can overcome
tamoxifen-induced cell cycle arrest in MCF-7 cells, whose
growth are normally highly sensitive to tamoxifen treat-
ment.
As estrogen can regulate the transition of breast epithelial
cells from G0 into S-phase of the cell cycle, we also exam-
ined the effects of HRG on cell cycle arrest induced by
TAM under conditions of low growth factors. Treatment
of MCF-7 cells with TAM for 24 hours reduced the fraction
of cells in S phase cells from 15.0% in cells that had been
cultured without serum for 24 hours to 4.7% (p = 3.4 ×
10-6). Treatment with HRG and E2 caused an increase in
the % of cells in S phase under these conditions (p < 0.001
for both). Treatment of MCF-7 cells with both TAM and
HRG caused the percentage of S phase cells to increase to
51.0% (p = 3.6 × 10-8 when compared with TAM alone).
This result was similar to increase in S-phase fraction
observed following treatment with HRG alone (Figure
2c). Together, the results of these experiments support the
hypothesis derived from the GSEA-analyzed human
microarray data proposing that the activation of the
downstream mediators of GF signaling contributes to
tamoxifen resistance in ER+ BC.
Gene expression profiling of HRG-treated MCF-7 cells 
identifies a similar expression profile to the highly 
proliferative (luminal-B) ER+ human breast cancer 
subtype
Previous microarray cluster analysis has shown that MCF-
7 cells are characterized by high expression of genes asso-BMC Medical Genomics 2009, 2:37 http://www.biomedcentral.com/1755-8794/2/37
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Western blot analysis for HER2 and HER3 and phosphorylated- HER2 (P-HER2), HER3 (P-HER3), AKT (P-AKT), S6 (P-S6) and  ERK (P-ERK) in serum starved MCF-7 cells treated with vehicle (C), tamoxifen [100 nM] (TAM), heregulin [10 ng/mL] (HRG)  or tamoxifen and heregulin (HRG-TAM) Figure 1
Western blot analysis for HER2 and HER3 and phosphorylated- HER2 (P-HER2), HER3 (P-HER3), AKT (P-
AKT), S6 (P-S6) and ERK (P-ERK) in serum starved MCF-7 cells treated with vehicle (C), tamoxifen [100 nM] 
(TAM), heregulin [10 ng/mL] (HRG) or tamoxifen and heregulin (HRG-TAM). (A) SK-BR3 cells were a positive 
control for HER2 overexpression. Compared with the SK-BR3 cells, the MCF7 cells do not overexpress HER2. (B) HRG alone 
or in combination with tamoxifen stimulates HER2, HER3, AKT, S6 and ERK phosphorylation as compared to vehicle and 
tamoxifen alone. These figures shows a representative blot from three separate western blots.
A
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Heregulin reverses the anti-proliferative effect of tamoxifen in clonogenic and anchorage independent assays Figure 2
Heregulin reverses the anti-proliferative effect of tamoxifen in clonogenic and anchorage independent assays. 
(A) Clonogenic assays: MCF-7 cells cultured at low density in standard 60 mm tissue culture plates. Cells were treated with 
vehicle (control), estrogen [1 nM] (E2), tamoxifen [100 nM] (TAM), heregulin [10 ng/mL] (HRG) or tamoxifen and heregulin 
(HRG-TAM) and colonies enumerated after 12 days. *p < 0.001 comparing tamoxifen-treated and heregulin with tamoxifen 
treated cultures. (B) Anchorage-independent growth assays: MCF-7 cells in 0.35% bactoagar with the different treat-
ments as above were grown on the bottom layer of 0.6% bactoagar in 35 mm tissue culture plates. Colonies were enumerated 
after 10 days. *P < 0.001 comparing tamoxifen-treated and heregulin with tamoxifen treatedcultures Graphs represent the 
mean colony number of nine dishes. Error bars indicate 95% CI. (C): Serum starved MCF-7 cells were treated with vehicle 
(control), tamoxifen [100 nM] (TAM), heregulin [10 ng/mL] (HRG) or tamoxifen and heregulin (HRG-TAM) for 24 hours and 
analyzed by flow cytometry. Each column represents the mean of the percentage of cells in G1 and S phase of the cell cycle 
from triplicate plates; error bars indicate 95%CI; * p < 0.001 comparing TAM and control; # p < 0.001 comparing TAM and 
HRG-TAM cells.
A B
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ciated with luminal epithelial cells, including the estrogen
receptor and that this cell line is an acceptable model for
the ER+/ERBB2- luminal tumors [22]. To examine
whether treatment of MCF-7 cell lines with HRG results in
enrichment of the ERBB2/GF signaling gene set and a
highly proliferative phenotype compared with untreated
MCF-7 cells, RNA was extracted for microarray analysis.
Gene expression profiles were then uploaded into GSEA
to determine if the ERBB2/GF signaling gene set was
highly correlated with the HRG-treated MCF-7 cells. This
was confirmed (p < 0.001, FDR = 0.16), supporting our
immunohistochemistry protein phosphorylation results.
Other gene sets supporting up-regulation of the cell cycle
function were also significantly enriched in the HRG-
treated MCF-7 cells (Additional file 4)
Finally, the quantitative assessment of the proliferation
activity of HRG-treated MCF-7 cells was compared with
untreated cells using the GGI. This analysis confirmed that
the HRG-treated cells had higher GGI scores (p = 0.02).
These data suggest that HRG-treated MCF-7 cells may be
useful as an in vitro model of the luminal-B ER+ BC sub-
type.
Discussion
In order to identify important underlying oncogenic path-
ways that could be contributing to the poor prognosis of
the luminal-B, ER+ BC subtype, we have used gene set
enrichment analysis (GSEA) to interrogate microarray data
derived from human breast cancer to generate potential
biological hypotheses. To our knowledge, this is the first
study specifically investigating the biology of the luminal-B
ER+ BC subtype. Here, we have shown that MCF-7 cells,
which are normally highly sensitive to tamoxifen treatment
in vitro, can, overcome tamoxifen-induced cell cycle arrest
when treated with the HER3 ligand heregulin (HRG),
which creates a scenario of growth factor pathway activa-
tion, supporting the GSEA-derived hypothesis. MCF-7 cells
treated with HRG also have higher expression of prolifera-
tion genes correlating with significantly higher GGI levels.
Furthermore, we subsequently confirmed enrichment of
the growth factor signaling gene set in the HRG-treated
MCF-7 cell lines which was associated with phosphorlyat-
ion of important downstream proteins commonly used to
identify activation of this pathway.
Whilst we curated the growth factor signaling gene set
from those genes associated with the ERBB2 over-express-
ing breast cancer subtype of Perou et al [9], it is possible
that this set of genes can be expressed in response to acti-
vation of any other growth factor or activating mutation
in the major signaling pathways downstream of growth
factor receptors. Two recent studies however, have dem-
onstrated the importance of ligand-induced signal ampli-
fication as an important mechanism of HER2 receptor
and pathway activation in tumors with low HER2 levels
[18,23]. Notably, MCF-7 cells are known to have low lev-
els of HER2 protein expression. Tamoxifen resistance in
ER+ BC is a major clinical problem and whilst mecha-
nisms of inherent and acquired tamoxifen resistance are
not fully understood, there is growing evidence of the sig-
nificance of activation of receptor tyrosine kinase path-
ways. As HER2 is such an important kinase in breast
cancer, it is not inconceivable that certain breast cancers
with low overall HER2 expression but with many acti-
vated receptors are still highly dependent on this pathway
for proliferation and growth. Our study provides evidence
that activation of growth factor signaling could be a signif-
icant contributor to the luminal-B phenotype of ER+ BC.
Further experiments to define if our observations are
mediated through HER2 or other members of the EGFR
family will be important to determine if targeting acti-
vated ERBB2 signaling in patients with the luminal-B phe-
notype could be of therapeutic benefit. A recent study
reported that the gene expression profile associated with
insulin-like growth factor treatment of MCF7 cells con-
tained significant overlap with gene signatures derived
from breast cancer cell lines that over-expressed EGFR and
ERBB2 [24]. This is not surprising as many growth factors
activate downstream ERK/MAPK and PI3K/AKT/mTOR
signaling but emphasizes that further clinical and labora-
tory studies will need to be performed to identify if there
is a predominant therapeutic target in this subtype of ER+
BC, or if multiple pathways will need to be inhibited to
produce clinical benefit in these patients.
The present study also illustrates the ability of generating a
biological hypothesis derived from the gene expression pro-
files of microarray-defined breast cancer molecular subtypes.
Heterogeneity of breast cancer clinical behavior and
response to tamoxifen has long been apparent to clinicians
despite positive expression of the estrogen receptor and its
related genes. Studies analyzing ER+ BC prognosis using
whole genome microarray data have suggested that ER+ BC
is biologically heterogeneous due to the influence of other
oncogenic pathways [2-4,6,9]. Thus far however, there has
been little research into the pathogenic mechanisms charac-
terizing the individual molecular subtypes apart from the
HER2 subtype. Oh and colleagues have proposed abnormal
apoptosis and interferon regulation as also contributing to
the luminal-B/poor prognostic ER+ BC phenotype [5]. Eluci-
dation of the underlying biological mechanisms is critical for
pinpointing an effective therapeutic strategy.
The current data supports the literature on the use of GSEA
as a valuable means of generating biological hypotheses uti-
lizing microarray data. A limitation of GSEA is that it relies
absolutely on the quality of the gene set that is being ana-
lyzed for enrichment and as it uses predefined gene sets, it
does not "discover" new information from the magnitude ofBMC Medical Genomics 2009, 2:37 http://www.biomedcentral.com/1755-8794/2/37
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data available. Other new bioinformatics methods that are
being developed will hopefully further our understanding of
the underlying oncogenic networks characterizing each of
the breast cancer molecular subtypes [25,26].
Conclusion
In summary, we propose that activation of growth factor
signaling contributes to the highly proliferative, relatively
tamoxifen-insensitive, luminal-B ER+ BC phenotype and
that this signaling is independent of HER2 over-expres-
sion. Our study suggests that for this subgroup of ER+
breast cancer patients, targeting this pathway and its
upstream mediators could be a useful therapeutic strategy
that should be explored in the clinical setting.
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